A PHASE 3, OPEN-LABEL, RANDOMIZED 2-ARM STUDY COMPARING THE CLINICAL EFFICACY
AND SAFETY OF NIRAPARIB WITH TEMOZOLOMIDE IN ADULT PARTICIPANTS WITH NEWLY-DIAGNOSED, MGMT UNMETHYLATED GLIOBLASTOMA
- Registry ID
- IVY-P3-24-021
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- NEUROTRIALS LLC
- Start date
- 2025-06-12
- Last update
- 2024-10-16
Conditions
Related clinical trials
- A PHASE 1/2 STUDY TO ASSESS BDTX-1535, AN ORAL EGFR INHIBITOR, IN PATIENTS
WITH GLIOBLASTOMA OR NON-SMALL CELL LUNG CANCER
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
OF OPTUNE® (TTFIELDS, 200 KHZ) CONCOMITANT WITH MAINTENANCE
TEMOZOLOMIDE AND PEMBROLIZUMAB VERSUS OPTUNE® CONCOMITANT WITH
MAINTENANCE TEMOZOLOMIDE AND PLACEBO FOR THE TREATMENT OF NEWLY
DIAGNOSED GLIOBLASTOMA
- A RANDOMIZED PHASE II STUDY ON INTRA-ARTERIAL CARBOPLATIN COMBINED WITH CAELYX COMPARED TO INTRA-ARTERIAL CARBOPLATIN COMBINED WITH ETOPOSIDE PHOSPHATE FOR PROGRESSING GLIOBLASTOMA AT FIRST OR SECOND RELAPSE.
- BIOMARKER AND TUMOR CELL CULTURE-DRIVEN PILOT TRIAL FOR TREATMENT OF RECURRENT GLIOBLASTOMA
- AN OPEN-LABEL, MULTICENTER, PHASE I STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY CLINICAL ACTIVITY OF RO7428731 IN PARTICIPANTS WITH GLIOBLASTOMA EXPRESSING MUTANT EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III
- A RANDOMIZED CONTROLLED TRIAL OF TAMOXIFEN VERSUS ETOPOSIDE FOR PATIENTS WITH FIRST RECURRENCE OF GLIOBLASTOMA MULTIFORME
View on source registry